IMAB I-MAB ADS (N Shares)

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab to Present at Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig.

I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.

Conference details are as follows:

Jefferies Global Healthcare Conference

Format: Fireside Chat and one-on-one meetings

Date: Thursday, June 5, 2025

Time: 3:45 PM ET

Webcast Link: Register

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit and follow us on and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors









EN
20/05/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Strengthens Givastomig Intellectual Property Portfolio through A...

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge Health by I-Mab ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it en...

July 17, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab to Present at the BTIG Virtual Biotechnology Conference

I-Mab to Present at the BTIG Virtual Biotechnology Conference ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025. Conference details are as follows: BTIG Virtual Biotechnology ConferenceFormat: Fireside Chat and one-on-one meetingsDate: Tuesday, July 29, 2025Time: 10:00 AM ETWebcast Lin...

July 14, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Co...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision...

July 2, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical...

I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research Monotherapy efficacy and safety profile provided backbone for clinical development strategy in 1L combination with nivolumab plus chemotherapy ROCKVILLE, MD, June 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced publication of the first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in Clinical Cancer...

June 30, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in ...

I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2nd Company to host investor event on July 8th ROCKVILLE, Md., June 26, 2025 (GLOBE ...

June 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch